A detailed history of China Universal Asset Management Co., Ltd. transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 9,409 shares of TBPH stock, worth $92,678. This represents 0.01% of its overall portfolio holdings.

Number of Shares
9,409
Previous 5,713 64.69%
Holding current value
$92,678
Previous $48,000 56.25%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$7.66 - $10.25 $28,311 - $37,884
3,696 Added 64.69%
9,409 $75,000
Q2 2024

Jul 19, 2024

SELL
$8.29 - $9.92 $32,082 - $38,390
-3,870 Reduced 40.38%
5,713 $48,000
Q1 2024

Apr 29, 2024

BUY
$8.22 - $11.59 $31,433 - $44,320
3,824 Added 66.4%
9,583 $86,000
Q4 2023

May 21, 2024

SELL
$8.58 - $11.4 $32,809 - $43,593
-3,824 Reduced 39.9%
5,759 $64,000
Q4 2023

Jan 23, 2024

BUY
$8.58 - $11.4 $37,769 - $50,182
4,402 Added 324.39%
5,759 $65,000
Q3 2023

May 21, 2024

BUY
$8.38 - $10.44 $5,028 - $6,264
600 Added 79.26%
1,357 $11,000
Q3 2023

Oct 30, 2023

BUY
$8.38 - $10.44 $5,028 - $6,264
600 Added 79.26%
1,357 $12,000
Q2 2023

May 21, 2024

SELL
$10.16 - $11.92 $1,584 - $1,859
-156 Reduced 17.09%
757 $7,000
Q2 2023

Jul 27, 2023

SELL
$10.16 - $11.92 $1,584 - $1,859
-156 Reduced 17.09%
757 $8,000
Q1 2023

May 21, 2024

BUY
$9.87 - $11.44 $2,260 - $2,619
229 Added 33.48%
913 $9,000
Q1 2023

Apr 27, 2023

BUY
$9.87 - $11.44 $2,260 - $2,619
229 Added 33.48%
913 $10,000
Q4 2022

May 21, 2024

SELL
$9.65 - $11.34 $85,875 - $100,914
-8,899 Reduced 92.86%
684 $7,000
Q4 2022

Jan 31, 2023

SELL
$9.65 - $11.34 $308 - $362
-32 Reduced 4.47%
684 $8,000
Q3 2022

Oct 21, 2022

BUY
$8.39 - $10.22 $6,007 - $7,317
716 New
716 $7,000

Others Institutions Holding TBPH

About Theravance Biopharma, Inc.


  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $658M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.